Provided here are links that highlight relevant milestones and news for Juvabis.

For more up-to-date information, please visit our LinkedIn profile.

Juvabis announces positive Clinical Phase 1 results of EBL-1003 in the Innovative Medicines Initiative ENABLE Consortium.

Click here for Press Release on LinkedIn


A vital class of antibiotics is on the verge of being saved thanks to European investment and collaboration

Interview with Founding CEO Dr Sven Hobbie as part of Antimicrobial Resistance campaign, World Antimicrobial Awareness Week, 2020


A very promising new antibiotic just started clinical trials

Researchers from ENABLE are hopeful about EBL-1003 because it has passed the stage at which most potential antibiotics fail.